Cannabidiol
ApprovedActive 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Lennox Gastaut Syndrome
Conditions
Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
Trial Timeline
Jul 7, 2021 → Mar 31, 2028
NCT ID
NCT05044819About Cannabidiol
Cannabidiol is a approved stage product being developed by Jazz Pharmaceuticals for Lennox Gastaut Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT05044819. Target conditions include Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02660255 | Pre-clinical | Completed |
| NCT05044819 | Approved | Active |
| NCT04447846 | Phase 2 | Completed |
| NCT02332655 | Phase 1/2 | Completed |
Competing Products
11 competing products in Lennox Gastaut Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + Perampanel | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Pre-clinical | 23 |
| Rufinamide (E2080) + Placebo | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Pre-clinical | 23 |
| Rufinamide | Eisai | Phase 3 | 77 |
| Rufinamide + Any other approved Antiepileptic Drug | Eisai | Phase 3 | 77 |
| ZX008 0.2 or 0.8 mg/kg/day + Matching Placebo | UCB | Phase 3 | 74 |
| Clobazam | Lundbeck | Phase 3 | 74 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Pre-clinical | 20 |
| GWP42003-P | Jazz Pharmaceuticals | Approved | 82 |
| Clemizole HCl + Placebo | Harmony Biosciences | Phase 3 | 72 |